Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) · Source last updated 2026-06-26
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
From first dose of IP through the last dose of IP (up to Day 29) plus 30 days.
What was measured
TEAEs of interest included capillary leak syndrome (CLS), cytokine release syndrome (CRS), decreased immunoglobulins (DI), elevated liver enzymes (ELE), embolic and thrombotic events (ETE), infections (INF), infusion reactions without considering duration (IRWCD), medication errors (ME), neurologic events (NE), neutropenia and febrile neutropenia (NFN), pancreatitis (PNC), tumor lysis syndrome, leukoencephalopathy, immunogenicity. Severity was graded according to the CTCAE version 4.03: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death.
Analysis population: Safety Analysis Set: who received protocol-specified therapy analyzed according to the treatment they received.
Groups in this outcome
HC3 Chemotherapy
One week of treatment with HC3 followed by 3 weeks of no treatment. The standard intensive consolidation chemotherapy course HC3 includes dexamethasone (10 mg/m\^2/day IV on Days 1-6), vincrisitne (1.5 mg/m\^2/day IV on Days 1 and 6), daunorubicin (30 mg/m\^2 IV over 24 hours on Day 5), methotrexate (1 g/m\^2 IV over 36 hours on Day 1), ifosfamide (800 mg/m\^2 IV for 1 hour on Days 2-4), and pegylated \[PEG\]-asparaginase (1000 U/m\^2 IV for 2 hours or IM on Day 6) or, if allergic, erwinia-asparaginase (20,000 units/m\^2 IV or IM every 48 hours for a total of 6 doses).
Blinatumomab
One 4-week cycle of blinatumomab 15 μg/m\^2/day as a continuous intravenous infusion (CIVI).
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
HC3 Chemotherapy
52
Blinatumomab
54
Reported measurements
CLS Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
1
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
CLS Events Grade ≥ 3
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
1
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
Serious CLS Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
1
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
Fatal CLS Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
CLS Events Leading to Discontinuation of IP
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
CLS Events Leading to Interruption of IP
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
CRS Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
1
Not reported
Not reported
Not reported
Not reported
Blinatumomab
2
Not reported
Not reported
Not reported
Not reported
CRS Events Grade ≥ 3
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
Serious CRS Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
Fatal CRS Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
CRS Events Leading to Discontinuation of IP
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
CRS Events Leading to Interruption of IP
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
DI Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
6
Not reported
Not reported
Not reported
Not reported
Blinatumomab
9
Not reported
Not reported
Not reported
Not reported
DI Events Grade ≥ 3
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
1
Not reported
Not reported
Not reported
Not reported
Blinatumomab
1
Not reported
Not reported
Not reported
Not reported
Serious DI Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
1
Not reported
Not reported
Not reported
Not reported
Fatal DI Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
DI Events Leading to Discontinuation of IP
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
DI Events Leading to Interruption of IP
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
ELE Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
15
Not reported
Not reported
Not reported
Not reported
Blinatumomab
7
Not reported
Not reported
Not reported
Not reported
ELE Events Grade ≥ 3
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
9
Not reported
Not reported
Not reported
Not reported
Blinatumomab
3
Not reported
Not reported
Not reported
Not reported
Serious ELE Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
1
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
Fatal ELE Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
ELE Events Leading to Discontinuation of IP
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
ELE Events Leading to Interruption of IP
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
ETE Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
4
Not reported
Not reported
Not reported
Not reported
ETE Events Grade ≥ 3
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
2
Not reported
Not reported
Not reported
Not reported
Serious ETE Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
Fatal ETE Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
ETE Events Leading to Discontinuation of IP
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
ETE Events Leading to Interruption of IP
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
INF Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
18
Not reported
Not reported
Not reported
Not reported
Blinatumomab
25
Not reported
Not reported
Not reported
Not reported
INF Events Grade ≥ 3
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
6
Not reported
Not reported
Not reported
Not reported
Blinatumomab
11
Not reported
Not reported
Not reported
Not reported
Serious INF Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
6
Not reported
Not reported
Not reported
Not reported
Blinatumomab
4
Not reported
Not reported
Not reported
Not reported
Fatal INF Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
IFN Events Leading to Discontinuation of IP
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
IFN Events Leading to Interruption of IP
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
IRWCD Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
4
Not reported
Not reported
Not reported
Not reported
Blinatumomab
37
Not reported
Not reported
Not reported
Not reported
IRWCD Events Grade ≥ 3
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
2
Not reported
Not reported
Not reported
Not reported
Serious IRWCD Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
1
Not reported
Not reported
Not reported
Not reported
Fatal IRWCD Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
IRWCD Events Leading to Discontinuation of IP
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
IRWCD Events Leading to Interruption of IP
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
ME Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
1
Not reported
Not reported
Not reported
Not reported
ME Events Grade ≥ 3
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
Serious ME Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
1
Not reported
Not reported
Not reported
Not reported
Fatal ME Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
ME Events Leading to Discontinuation of IP
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
ME Events Leading to Interruption of IP
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
1
Not reported
Not reported
Not reported
Not reported
NE Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
15
Not reported
Not reported
Not reported
Not reported
Blinatumomab
26
Not reported
Not reported
Not reported
Not reported
NE Events Grade ≥ 3
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
1
Not reported
Not reported
Not reported
Not reported
Blinatumomab
3
Not reported
Not reported
Not reported
Not reported
Serious NE Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
1
Not reported
Not reported
Not reported
Not reported
Blinatumomab
5
Not reported
Not reported
Not reported
Not reported
Fatal NE Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
NE Events Leading to Discontinuation of IP
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
2
Not reported
Not reported
Not reported
Not reported
NE Events Leading to Interruption of IP
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
1
Not reported
Not reported
Not reported
Not reported
Blinatumomab
3
Not reported
Not reported
Not reported
Not reported
NFN Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
28
Not reported
Not reported
Not reported
Not reported
Blinatumomab
12
Not reported
Not reported
Not reported
Not reported
NFN Events Grade ≥ 3
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
27
Not reported
Not reported
Not reported
Not reported
Blinatumomab
11
Not reported
Not reported
Not reported
Not reported
Serious NFN Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
12
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
Fatal NFN Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
NFN Events Leading to Discontinuation of IP
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
NFN Events Leading to Interruption of IP
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
PNC Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
1
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
PNC Events Grade ≥ 3
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
1
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
Serious PNC Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
1
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
Fatal PNC Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
PNC Events Leading to Discontinuation of IP
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
PNC Events Leading to Interruption of IP
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
Tumour Lysis Syndrome Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
Leukoencephalopathy Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
Immunogenicity Events
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
HC3 Chemotherapy
0
Not reported
Not reported
Not reported
Not reported
Blinatumomab
0
Not reported
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0
title
CLS Events
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0
title
CLS Events Grade ≥ 3
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0
title
Serious CLS Events
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
Fatal CLS Events
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
CLS Events Leading to Discontinuation of IP
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
CLS Events Leading to Interruption of IP
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
2
title
CRS Events
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
CRS Events Grade ≥ 3
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
Serious CRS Events
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
Fatal CRS Events
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
CRS Events Leading to Discontinuation of IP
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
CRS Events Leading to Interruption of IP
denoms
counts
group Id
OG000
value
52
group Id
OG001
value
54
units
Participants
description
TEAEs of interest included capillary leak syndrome (CLS), cytokine release syndrome (CRS), decreased immunoglobulins (DI), elevated liver enzymes (ELE), embolic and thrombotic events (ETE), infections (INF), infusion reactions without considering duration (IRWCD), medication errors (ME), neurologic events (NE), neutropenia and febrile neutropenia (NFN), pancreatitis (PNC), tumor lysis syndrome, leukoencephalopathy, immunogenicity. Severity was graded according to the CTCAE version 4.03: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death.
groups
description
One week of treatment with HC3 followed by 3 weeks of no treatment. The standard intensive consolidation chemotherapy course HC3 includes dexamethasone (10 mg/m\^2/day IV on Days 1-6), vincrisitne (1.5 mg/m\^2/day IV on Days 1 and 6), daunorubicin (30 mg/m\^2 IV over 24 hours on Day 5), methotrexate (1 g/m\^2 IV over 36 hours on Day 1), ifosfamide (800 mg/m\^2 IV for 1 hour on Days 2-4), and pegylated \[PEG\]-asparaginase (1000 U/m\^2 IV for 2 hours or IM on Day 6) or, if allergic, erwinia-asparaginase (20,000 units/m\^2 IV or IM every 48 hours for a total of 6 doses).
id
OG000
title
HC3 Chemotherapy
description
One 4-week cycle of blinatumomab 15 μg/m\^2/day as a continuous intravenous infusion (CIVI).
id
OG001
title
Blinatumomab
param Type
NUMBER
population Description
Safety Analysis Set: who received protocol-specified therapy analyzed according to the treatment they received.
reporting Status
POSTED
time Frame
From first dose of IP through the last dose of IP (up to Day 29) plus 30 days.
Triangle